Migraine Trial, Recruiting (NCT06684249)

Migraine Trial, Recruiting NCT06684249 Sponsor: Zagazig University Condition: Migraine

Printed from Voxsanity (voxsanity.com.au) — NCT06684249 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Migraine

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults between 18 and 65 years old.
People who have been diagnosed with chronic migraine, meaning they have headaches on 15 or more days per month for more than three months, with at least 8 of those days being migraine days.
People who are able to understand and agree to the study requirements and give their consent to participate.
People who have not made any changes to their migraine prevention medications in the last 3 months.

Who may not be able to join:

People who have a known allergy or bad reaction to local anesthetics (numbing medicines) or Botulinum toxin (Botox).
People who have had a nerve block procedure or Botox treatment within the last 6 months.
People who have a significant mental health or neurological condition that could affect their ability to take part in or be assessed during the study (confirm with trial site).
People who are currently pregnant or breastfeeding.
People for whom either of the treatments used in this trial is medically unsuitable based on the official guidelines for those treatments (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ahmed Bessar, MD, PhD, Assistant Professor of Diagnostic and Interventional Radiology, Zagazig Uni.

Phone: +201000089595

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06684249

Sponsor: Zagazig University

Phase: Not Applicable

Status: Recruiting

Condition: Migraine

Trial contact: +201000089595

More information: https://clinicaltrials.gov/study/NCT06684249

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults between 18 and 65 years old.
People who have been diagnosed with chronic migraine, meaning they have headaches on 15 or more days per month for more than three months, with at least 8 of those days being migraine days.
People who are able to understand and agree to the study requirements and give their consent to participate.
People who have not made any changes to their migraine prevention medications in the last 3 months.

Who may not be able to join:

People who have a known allergy or bad reaction to local anesthetics (numbing medicines) or Botulinum toxin (Botox).
People who have had a nerve block procedure or Botox treatment within the last 6 months.
People who have a significant mental health or neurological condition that could affect their ability to take part in or be assessed during the study (confirm with trial site).
People who are currently pregnant or breastfeeding.
People for whom either of the treatments used in this trial is medically unsuitable based on the official guidelines for those treatments (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Zagazig University

Registry

ClinicalTrials.gov

Start date

10 November 2024

Est. completion

10 May 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Reduction in Monthly Migraine Days

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov